Nominations Open! Help Us Recognize Leaders, Innovators, & Advocates

The Reagan-Udall Foundation for the FDA, in collaboration with the Food and Drug Administration (FDA), will host a virtual, public workshop to explore opportunities to optimize therapeutic development to address primary mitochondrial diseases.

The Reagan-Udall Foundation for the FDA, in collaboration with the Food and Drug Administration (FDA), hosted a public webinar as part of a series of webinars for FDA-issued guidance related to real-world evidence (RWE).

On October 30, 2024, we held a one-hour session on IMEDS, a flagship program of the Regan-Udall Foundation for the FDA.

On October 7, we hosted a virtual public meeting to hear insights on the Final Rule on Requirements for Additional Traceability Records from both FDA leadership and other experts from across food industry sectors.

The Reagan-Udall Foundation for the FDA, in support of FDA’s ongoing focus on PTSD, convened “Advancing Treatments for Post-Traumatic Stress Disorder,” a public meeting with stakeholder comment.

The Reagan-Udall Foundation for the FDA, in collaboration with FDA’s Rare Disease Innovation Hub, hosted a public meeting on October 16, 2024.

The Reagan-Udall Foundation for the FDA conducted a series of five closed-door virtual roundtable conversations with biosimilar developers to explore emerging areas of regulatory science and to create a space for active discussion and exploration between FDA and biosimilar developers.